Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease

被引:24
作者
Lomer, Miranda C. E. [2 ,3 ]
Cook, William B. [1 ]
Jan-Mohamed, Hamid Jan B. [2 ,4 ]
Hutchinson, Carol [1 ]
Liu, Ding Yong [5 ]
Hider, Robert C. [5 ]
Powell, Jonathan J. [1 ]
机构
[1] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England
[2] Kings Coll London, Div Nutr Sci, London SE1 9NH, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London, England
[4] Univ Sains Malaysia, Sch Hlth Sci, Kelantan, Malaysia
[5] Kings Coll London, Div Pharmaceut Sci, London SE1 9NH, England
关键词
Inflammatory bowel disease; Iron absorption; Iron status; Haematological parameters; Iron deficiency; NONTRANSFERRIN-BOUND IRON; CROHNS-DISEASE; INTRAVENOUS IRON; SERUM FERRITIN; INDUCED COLITIS; ANEMIA; DEFICIENCY; SUPPLEMENTATION; ERYTHROPOIETIN; STRESS;
D O I
10.1017/S0007114511004971
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Fe deficiency and Fe-deficiency anaemia are common in patients with inflammatory bowel disease (IBD). Traditional clinical markers of Fe status can be skewed in the presence of inflammation, meaning that a patient's Fe status can be misinterpreted. Additionally, Fe absorption is known to be down-regulated in patients with active IBD. However, whether this is the case for quiescent or mildly active disease has not been formally assessed. The present study aimed to investigate the relationship between Fe absorption, Fe requirements and standard haematological indices in IBD patients without active disease. A group of twenty-nine patients with quiescent or mildly active IBD and twenty-eight control subjects undertook an Fe absorption test that measured sequential rises in serum Fe over 4 h following ingestion of 200 mg ferrous sulphate. At baseline, serum Fe, transferrin saturation, non-transferrin-bound Fe (NTBI), ferritin and soluble transferrin receptor were all measured. Thereafter (30-240 min), only serum Fe and NTBI were measured. Fe absorption did not differ between the two groups (P=0.9; repeated-measures ANOVA). In control subjects, baseline haematological parameters predicted Fe absorption (i.e. Fe requirements), but this was not the case for patients with 1131). Fe absorption is normal in quiescent or mildly active IBD patients but standard haematological parameters do not accurately predict Fe requirements.
引用
收藏
页码:1806 / 1811
页数:6
相关论文
共 50 条
[31]   Prevalence of Anemia and Iron Deficiency in Romanian Patients with Inflammatory Bowel Disease: a Prospective Multicenter Study [J].
Lupu, Alexandru ;
Diculescu, Mircea ;
Diaconescu, Razvan ;
Tantau, Marcel ;
Tantau, Alina ;
Visovan, Ioana ;
Gheorghe, Cristian ;
Lupei, Cristina ;
Gheorghe, Liana ;
Cerban, Razvan ;
Vadan, Roxana ;
Goldis, Adrian .
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2015, 24 (01) :15-20
[32]   Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia [J].
Gianluca Abbati ;
Federica Incerti ;
Chiara Boarini ;
Francesca Pileri ;
Davide Bocchi ;
Paolo Ventura ;
Elena Buzzetti ;
Antonello Pietrangelo .
Internal and Emergency Medicine, 2019, 14 :423-431
[33]   Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease [J].
Nordfjeld, Kim ;
Andreasen, Hans ;
Thomsen, Lars L. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 :43-51
[34]   Comparison of the Efficacies of Parenteral Iron Sucrose and Oral Iron Sulfate for Anemic Patients with Inflammatory Bowel Disease in Korea [J].
Han, Yoo Min ;
Yoon, Hyuk ;
Shin, Cheol Min ;
Koh, Seong-Joon ;
Im, Jong Pil ;
Kim, Byeong Gwan ;
Kim, Joo Sung ;
Jung, Hyun Chae .
GUT AND LIVER, 2016, 10 (04) :562-568
[35]   Efficacy of intravenous iron in treating iron deficiency anaemia in patients with inflammatory bowel disease. Are there predictors of response? [J].
Ferreiro Iglesias, Rocio ;
Barreiro de Acosta, Manuel ;
Seijo-Rios, Susana ;
Lorenzo, Aurelio ;
Dominguez Munoz, J. Enrique .
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2011, 103 (05) :245-249
[36]   Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia [J].
Maria Huguet, Jose ;
Cortes, Xavier ;
Maia Bosca-Watts, Marta ;
Munoz, Margarita ;
Maroto, Nuria ;
Iborra, Marisa ;
Hinojosa, Esther ;
Capilla, Maria ;
Asencio, Carmina ;
Amoros, Cirilo ;
Maria Paredes, Jose .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (10)
[37]   Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol [J].
Loveikyte, Roberta ;
Duijvestein, Marjolijn ;
Mujagic, Zlatan ;
Goetgebuer, Rogier L. ;
Gerard, Dijkstra ;
van der Meulen-de Jong, Andrea E. .
BMJ OPEN, 2024, 14 (01)
[38]   Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain [J].
Arguelles-Arias, Federico ;
Bermejo, Fernando ;
Borras-Blasco, Joaquin ;
Domenech, Eugeni ;
Sicilia, Beatriz ;
Huguet, Jose M. ;
de Arellano, Antonio Ramirez ;
Valentine, William J. ;
Hunt, Barnaby .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[39]   Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease [J].
Koutroubakis, Ioannis E. ;
Oustamanolakis, Pantelis ;
Karakoidas, Christos ;
Mantzaris, Gerassimos J. ;
Kouroumalis, Elias A. .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (08) :2327-2331
[40]   Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland [J].
Aksan, Ayseguel ;
Schoepfer, Alain ;
Juillerat, Pascal ;
Vavricka, Stephan ;
Bettencourt, Miguel ;
Ramirez de Arellano, Antonio ;
Gavata, Simona ;
Morin, Neige ;
Valentine, William J. ;
Hunt, Barnaby .
ADVANCES IN THERAPY, 2021, 38 (01) :660-677